Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03908125 · ClinicalTrials.gov registry record · NA
Post Approval Study of the Eversense® Continuous Glucose Monitoring
A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, sponsored by Senseonics.
- Completed
- Registry status
- NA
- Development phase
- 273
- Enrollment target
- 17
- Study locations
NCT03908125: Completed NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, sponsored by Senseonics.
NCT03908125 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus that has completed, run by Senseonics. The registered enrollment target is 273 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03908125, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, has completed, sponsored by Senseonics.
- COMPLETED
- Registry status
- NA
- Development phase
- 273 participants
- Enrollment target
- 17
- Study locations
Study Summary
A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the Eversense® CGM System
Primary Outcome
The primary safety endpoint was the incidence of the composite of infection, secondary procedures to remove the Sensor, or procedure-related adverse events of at least moderate severity, with a performance goal of \< 4%.
Conditions Studied
Interventions
- DEVICE Eversense® CGM System
Study Locations (17)
Texas
- Texas Diabetes and Endocrinology - Austin
- Clinical Research Solution, LLC - Cypress
- Javara, Inc - Houston
- Diabetes and Glandular Disease Clinic - San Antonio
- Consano Clinical Research, LLC - Shavano Park
North Carolina
- Physicians East - Greenville
- PMG Research of Wilmington, LLC - Wilmington
California
- Hoag Memorial Hospital Presbyterian/Mary Dick Allen Diabetes Center - Newport Beach
Colorado
- Denver Endocrinology, Diabetes & Thyroid Center - Englewood
Florida
- The Center for Diabetes and Endocrine Care - Fort Lauderdale
Georgia
- Atlanta Diabetes Associates - Atlanta
Maryland
- MODEL Clinical research - Baltimore
Michigan
- Metro Detroit Endocrinology Center - Dearborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2024-02-01 |
| Phase | NA |
What the finished NCT03908125 record still lists
NCT03908125 is an interventional study that assigns participants to a tested intervention. The registered 273 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Eversense® CGM System is the first listed.
NCT03908125 lists 17 locations in 12 states (Texas, North Carolina, California).
Frequently Asked Questions
What is clinical trial NCT03908125 about?
NCT03908125 is a clinical study titled "Post Approval Study of the Eversense® Continuous Glucose Monitoring". A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the Eversense® CGM System
What is the current status of trial NCT03908125?
This trial is currently completed. It is a NA study. The enrollment target is 273 participants. The study started on 2019-03-19. Estimated completion is 2024-02-01.
What conditions does trial NCT03908125 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03908125?
The interventions under investigation include: Eversense® CGM System (DEVICE).
Who is sponsoring clinical trial NCT03908125?
This trial is sponsored by Senseonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03908125 being conducted?
This trial has 17 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03908125's enrollment target sits among peer trials
273 132nd of 348 higher than 217 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07229430 · 273 participants · NA
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI